Integral Health Asset Management LLC Has $5.86 Million Position in Bruker Co. (NASDAQ:BRKR)

Integral Health Asset Management LLC lessened its holdings in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 25.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 100,000 shares of the medical research company's stock after selling 35,000 shares during the quarter. Integral Health Asset Management LLC owned approximately 0.07% of Bruker worth $5,862,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Brown Advisory Inc. raised its position in Bruker by 10.1% during the fourth quarter. Brown Advisory Inc. now owns 2,026,712 shares of the medical research company's stock valued at $118,806,000 after acquiring an additional 185,912 shares in the last quarter. Geode Capital Management LLC grew its holdings in Bruker by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 2,013,741 shares of the medical research company's stock valued at $118,081,000 after purchasing an additional 20,273 shares during the last quarter. FIL Ltd grew its holdings in Bruker by 262.3% during the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock valued at $114,978,000 after purchasing an additional 1,420,102 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Bruker by 22.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,687,364 shares of the medical research company's stock valued at $98,914,000 after purchasing an additional 313,171 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in Bruker by 10.6% during the fourth quarter. Ameriprise Financial Inc. now owns 1,615,358 shares of the medical research company's stock valued at $94,692,000 after purchasing an additional 154,768 shares during the last quarter. Institutional investors own 79.52% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Guggenheim reiterated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Citigroup lowered their price target on Bruker from $75.00 to $50.00 and set a "buy" rating on the stock in a report on Monday, April 7th. Barclays lowered their price target on Bruker from $50.00 to $46.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Stifel Nicolaus lowered their price objective on shares of Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a research note on Thursday, May 8th. Finally, The Goldman Sachs Group lowered their price objective on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $60.10.

Bruker Stock Performance

BRKR stock traded up $0.84 during midday trading on Friday, hitting $37.53. The stock had a trading volume of 1,786,228 shares, compared to its average volume of 1,604,384. The firm has a market capitalization of $5.69 billion, a price-to-earnings ratio of 49.38, a P/E/G ratio of 2.16 and a beta of 1.23. Bruker Co. has a 52 week low of $34.10 and a 52 week high of $78.94. The stock has a 50-day simple moving average of $40.33 and a 200 day simple moving average of $50.45. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical research company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.46 by $0.01. The firm had revenue of $801.40 million during the quarter, compared to analysts' expectations of $763.83 million. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Bruker's quarterly revenue was up 11.0% compared to the same quarter last year. During the same period last year, the business earned $0.53 earnings per share. As a group, equities research analysts anticipate that Bruker Co. will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Monday, June 16th will be issued a dividend of $0.05 per share. The ex-dividend date is Monday, June 16th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.53%. Bruker's payout ratio is presently 38.46%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.